Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice.
Sign Up to like & getrecommendations! Published in 2018 at "Chemico-biological interactions"
DOI: 10.1016/j.cbi.2018.09.011
Abstract: Fasiglifam (TAK-875), a G protein-coupled receptor 40 (GPR40) agonist, was a drug candidate for type 2 diabetes. However, its development was terminated in phase 3 trials due to liver safety concerns. Although TAK-875 was reported… read more here.
Keywords: tak 875; acute liver; liver injury; 875 induced ... See more keywords
Investigation of the pharmacokinetics and metabolic fate of Fasiglifam (TAK-875) in male and female rats following oral and intravenous administration
Sign Up to like & getrecommendations! Published in 2023 at "Xenobiotica"
DOI: 10.1080/00498254.2023.2179952
Abstract: Abstract The metabolism and pharmacokinetics of fasiglifam (TAK-875, 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid), a selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist, were studied following intravenous (5 mg/kg) and oral administration (10 and 50 mg/kg) to male and female Sprague… read more here.
Keywords: female rats; rats following; following oral; tak 875 ... See more keywords